Cancer News and Research

Latest Cancer News and Research

Arno Therapeutics closes private placement to advance cancer treatment

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced that it has closed a private placement of its securities resulting in gross proceeds to the company of over $15 million.

14 Sep 2010

Study finds new therapeutic target for polycystic kidney disease

In work suggesting a new approach to treating polycystic kidney disease (PKD), a leading cause of kidney failure, researchers at Children's Hospital Boston were able to block the formation of fluid-filled cysts, the hallmark of the disease, in a mouse model. Their findings, using a compound that inhibits a receptor known as c-Met, will be published in the September 13th online edition of the Journal of Clinical Investigation.

14 Sep 2010

Pharmacyclics reports $9.3 million increase in total revenue for 2010 fiscal year

Pharmacyclics, Inc. today reported financial results for its fiscal year and fourth quarter which ended June 30, 2010.

14 Sep 2010

High dose peretinoin reduces recurrence of HCC after surgical resection or ablation in HCV positive patients

Kowa Company, Ltd. announced today that the results of a Phase II/III trial showed that high dose peretinoin (NIK-333) given daily for up to 96 weeks reduced the recurrence of hepatocellular carcinoma (HCC) after surgical resection or ablation in hepatitis C virus (HCV) positive patients when compared to placebo.

13 Sep 2010

Provectus's PV-10 Phase 2 data to be presented at 7th International Melanoma Research Congress

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at the 7th International Melanoma Research Congress in Sydney, Australia, on November 4, 2010 at 4:30 p.m., as part of the 4th Interdisciplinary Melanoma & Skin Cancer Centres Meeting,

13 Sep 2010

Merit Medical Systems acquires BioSphere Medical

Merit Medical Systems, Inc. today announced the completion of its acquisition of BioSphere Medical, Inc., a leading developer and marketer of embolotherapeutic products for the treatment of uterine fibroids, hypervascularized tumors, and arteriovenous malformations.

13 Sep 2010

North Mississippi IRB approves CEL-SCI's Multikine Phase III clinical trial for head and neck cancer

CEL-SCI Corporation announced today it has received approval from the North Mississippi Health Services Institutional Review Board ("IRB") to begin enrollment of subjects for a Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. An IRB is a group formally designated by an institution to review and monitor research involving human subjects and to ensure protection of their rights and welfare.

13 Sep 2010

Biosystems International announces merger with MicroBioChips

Biosystems International (BSI), a biotechnology company specializing in the discovery of novel monoclonal antibody based diagnostics, announces its merger with the company MicroBioChips (MBC) by contribution of assets.

13 Sep 2010

Synta expands STA-9090 Phase 2 clinical trial in NSCLC

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it was expanding its Phase 2 clinical trial of STA-9090 in patients with Stage IIIB and Stage IV non-small cell lung cancer (NSCLC) from up to 69 patients to up to 146 patients based on encouraging activity observed in the first stage of the two stage clinical trial.

13 Sep 2010

U-Systems granted EU marketing approval for somo•v Automated Breast Ultrasound system

U-Systems, the leader in automated breast ultrasound, today announced that it has received approval to market the somo•v™ Automated Breast Ultrasound (ABUS) system as an adjunct to mammography for screening asymptomatic women for breast cancer in the European Union.

13 Sep 2010

American Cancer Society announces details of new campaign

The American Cancer Society, the official sponsor of birthdays, today announced details of a unique new campaign that marks the next phase of the Society's movement for More Birthdays. Over the past several months, dozens of the biggest names in music and art have come together, inspired by the efforts of the American Cancer Society, its supporters and everyone affected by cancer, to generously donate their talent and artwork to help amplify the voice of the More Birthdays movement.

13 Sep 2010

Genoptix to participate 2010 UBS Global Life Sciences Conference

Genoptix, Inc., a specialized laboratory services provider, today announced the Company's participation at the 2010 UBS Global Life Sciences Conference at the Grand Hyatt Hotel in New York City, to be held September 20-22, 2010.

13 Sep 2010

Regis to kick off Clip for the Cure campaign to raise money, awareness for breast cancer research

In October, Regis Corporation, the global leader in the haircare industry, will kick off its annual Clip for the Cure, a month-long campaign to raise money and awareness for breast cancer research in support of National Breast Cancer Awareness Month. To date, the company's dedicated stylists and clients have raised more than $6.5 million for the cause.

13 Sep 2010

Geron, UCS collaborate to develop hESC-derived chondrocytes for cartilage damage, joint disease treatment

Geron Corporation today announced that the company has entered into a collaboration with University Campus Suffolk (UCS) in the U.K. to develop human embryonic stem cell-derived chondrocytes for the treatment of cartilage damage and joint disease.

13 Sep 2010

Jennerex reports positive interim data from trial of JX-594 and sorafenib for liver cancer

Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada.

13 Sep 2010

Geron signs worldwide, exclusive license agreement with University of Edinburgh

Geron Corporation today announced that it has entered into a worldwide, exclusive license agreement with the University of Edinburgh covering technology that allows the efficient production of chondrocytes (cartilage forming cells) from human pluripotent stem cells.

13 Sep 2010

Pro-Pharmaceuticals engages Numoda Corporation to optimize DAVANAT Phase III clinical trial

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that it has engaged the Numoda Corporation, a leading information, process and logistics management company, to oversee the Phase III clinical trial of DAVANAT and 5-FU compared with the standard of care in the treatment of patients with advanced, metastatic colorectal cancer.

13 Sep 2010

Incyte Corporation enters SPA agreement with FDA for INCB18424 inhibitor

Incyte Corporation announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) for the design of a pivotal Phase III trial for its JAK1 and JAK2 inhibitor, INCB18424 in patients with polycythemia vera (PV), a blood cancer that belongs to a group of diseases known as myeloproliferative neoplasms (MPNs).

13 Sep 2010

ARIAD commences ponatinib Phase 2 clinical trial in Ph+ ALL and chronic myeloid leukemia

ARIAD Pharmaceuticals, Inc. today announced the initiation of the pivotal Phase 2 clinical trial of its investigational pan-BCR-ABL inhibitor, ponatinib (previously known as AP24534), in patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL).

13 Sep 2010

PDL BioPharma announces conversion rate adjustment for Convertible Senior Notes due 2012

PDL BioPharma, Inc. today announced an adjustment to the conversion rate for its 2.00% Convertible Senior Notes due February 15, 2012 (the 2012 Notes) effective September 16, 2010 in connection with the special dividend to be paid on October 1, 2010 to all stockholders who own shares of PDL on September 15, 2010, the record date.

13 Sep 2010

Cancer News and Research

Latest Cancer News and Research

Arno Therapeutics closes private placement to advance cancer treatment

Study finds new therapeutic target for polycystic kidney disease

Pharmacyclics reports $9.3 million increase in total revenue for 2010 fiscal year

High dose peretinoin reduces recurrence of HCC after surgical resection or ablation in HCV positive patients

Provectus's PV-10 Phase 2 data to be presented at 7th International Melanoma Research Congress

Merit Medical Systems acquires BioSphere Medical

North Mississippi IRB approves CEL-SCI's Multikine Phase III clinical trial for head and neck cancer

Biosystems International announces merger with MicroBioChips

Synta expands STA-9090 Phase 2 clinical trial in NSCLC

U-Systems granted EU marketing approval for somo•v Automated Breast Ultrasound system

American Cancer Society announces details of new campaign

Genoptix to participate 2010 UBS Global Life Sciences Conference

Regis to kick off Clip for the Cure campaign to raise money, awareness for breast cancer research

Geron, UCS collaborate to develop hESC-derived chondrocytes for cartilage damage, joint disease treatment

Jennerex reports positive interim data from trial of JX-594 and sorafenib for liver cancer

Geron signs worldwide, exclusive license agreement with University of Edinburgh

Pro-Pharmaceuticals engages Numoda Corporation to optimize DAVANAT Phase III clinical trial

Incyte Corporation enters SPA agreement with FDA for INCB18424 inhibitor

ARIAD commences ponatinib Phase 2 clinical trial in Ph+ ALL and chronic myeloid leukemia

PDL BioPharma announces conversion rate adjustment for Convertible Senior Notes due 2012

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in